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Background-—Rheumatoid arthritis (RA) is associated with heightened mortality due to atherosclerotic cardiovascular disease
(CVD). Inflammatory pathways in RA negatively affect vascular physiology and promote metabolic disturbances that contribute to
CVD. We hypothesized that the peroxisome proliferator activated receptor-c (PPAR-c) pioglitazone could promote potent
vasculoprotective and anti-inflammatory effects in RA.
Methods and Results-—One hundred forty-three non-diabetic adult RA patients (76.2% female, age 55.212.1 [meanSD]) on stable
RAstandardofcare treatmentwereenrolled ina randomized,double-blindplacebocontrolledcrossover trial of45 mgdailypioglitazone
versusplacebo,with a3-monthduration/armanda2-monthwashout period. Pulsewavevelocity of theaorta (PWV), brachial arteryflow
mediated dilatation (FMD), nitroglycerin mediated dilatation (NMD), microvascular endothelial function (reactive hyperemia index
[RHI]), and circulating biomarkers of inflammation, insulin resistance, and atherosclerosis risk all were quantified. RA disease activity
was assessed with the 28-Joint Count Disease Activity Score (DAS-28) C-reactive protein (CRP) and the Short Form (36) Health Survey
quality of life questionnaire. When added to standard of care RA treatment, pioglitazone significantly decreased pulse wave velocity (ie,
aortic stiffness) (P=0.01), while FMD and RHI remained unchanged when compared to treatment with placebo. Further, pioglitazone
significantly reduced RA disease activity (P=0.02) and CRP levels (P=0.001), while improving lipid profiles. The drug waswell tolerated.
Conclusions-—Addition of pioglitazone to RA standard of care significantly improves aortic elasticity and decreases inflammation
and disease activity with minimal safety issues. The clinical implications of these findings remain to be established.
Clinical Trial Registration-—URL: ClinicalTrials.gov Unique Identifier: NCT00554853. ( J Am Heart Assoc. 2013;2:e000441 doi:
10.1161/JAHA.113.000441)
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R heumatoid arthritis (RA), a chronic inflammatory diseasethat affects 1% of the population in the United States,
is associated with significant levels of functional disability,
joint destruction, and loss of productivity. RA is also
associated with enhanced mortality, which is predominantly
due to accelerated atherosclerotic cardiovascular disease
(CVD).1–4 Indeed, women with RA are twice as likely to suffer
myocardial infarction (MI) compared to women without RA,
and the risk is considered equivalent to the one observed in
diabetes mellitus (DM).2 Largely due to this heightened CVD
risk, the overall life expectancy in RA is significantly
reduced.2,5,6 The Framingham risk equation does not fully
account for the enhanced CVD risk in RA,7 which appears to
convey a risk beyond that attributable to standard risk
factors. As such, it has been proposed that immune
dysregulation, inflammation, and metabolic disturbances
characteristic of RA play an important role in the development
of endothelial dysfunction, plaque progression, and acute
coronary syndromes (ACS).8 Indeed, chronic inflammation has
been firmly associated with endothelial cell (EC) activation
and vascular dysfunction, leading to noncompliance of vessels
and development of atheroma. However, the reasons for the
dramatic increase in CVD in RA are not totally understood and
appear to be complex.
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ORIGINAL RESEARCH
While growing evidence suggests that disease modifying
antirheumatic drugs (DMARDs) and various biologic agents
may decrease CV risk in RA,9–11 these drugs can also pose
significant risks to selected RA patients, are not accessible to
all patients, and their long-term protective effects on the
endothelium are uncertain.12 Therefore, it is important to
identify therapeutic targets that are antiatherogenic without
causing significant immunosuppression.
The thiazolidinediones (TZD) are a class of drugs used in the
treatment of type 2 diabetes mellitus (DM). These drugs are
potent peroxisome proliferator-activated receptor-c (PPAR-c)
agonists with significant pleiotropic effects on the vasculature
and on inflammatory pathways that are both antiatherogenic
and anti-inflammatory.13 We hypothesized that TZDs could
significantly improve endothelial function and CV risk in RA
and might represent an important preventive strategy for this
potentially fatal complication in individuals with this disease.
Given the anti-inflammatory properties reported previously by
PPAR-c agonists both in vitro and in vivo,13–18 we also
proposed that TZDs could ameliorate RA disease activity.
This study assessed the efficacy of TZDs with regards to
modification of vascular function, biomarkers of CV risk and
disease activity in a cohort of patients with stable RA.
Methods
Subjects
The study protocol complied with the Declaration of Helsinki
and was approved by the University of Michigan Medical
Institutional Review Board. All participants signed informed
consent. Subjects fulfilling the 1987 American College of
Rheumatology diagnostic criteria for RA19 were recruited from
the Rheumatology clinic at the University of Michigan and by
advertisement. For inclusion, stable doses (>3 months prior
to enrollment) of corticosteroids, DMARDs and/or biological
agents were required. Subjects were excluded if they were
current smokers or had smoked within 6 months prior to
enrollment, had significant hepatic or renal impairment,
diabetes mellitus, congestive heart failure (NYHA class III or
IV), or acute infection. Subjects treated with lipid-lowering
drugs were required to be on stable doses for at least
6 months prior to enrollment. Women of reproductive age
were excluded if pregnant or lactating, and were required to
be on adequate contraception to be enrolled.
Study Protocol
The study was a single-center, randomized, double-blind,
placebo-controlled, crossover treatment trial of 45 mg daily of
pioglitazone. Pioglitazone and placebo tablets were provided
by Takeda Pharmaceutical Company. Patients were treated for
3 months with pioglitazone or placebo, underwent a washout
period of 8 weeks, and then crossed over to the other arm for
an additional 3 months. Patients typically took 30 mg daily of
pioglitazone for 2 weeks, followed by an increase to 45 mg
daily for the rest of the treatment arm. Functional and serum
biomarkers of vascular damage, atherosclerosis risk, and RA
disease activity were assessed at baseline and at 3, 5, and
8 months after enrollment using the 28-Joint Count Disease
Activity Score C-reactive protein (DAS28-CRP). Safety visits
occurred at 1 and 6 months postenrollment (see Figure 1 for
detailed protocol).
Vascular function assessment
Studies were conducted at the University of Michigan
Research Vascular Laboratory in a temperature-controlled
room. Prior to testing, patients were instructed to fast and to
hold vasoactive drugs for at least 12 h. Detailed methodology
has been previously described by our group.20,21
Pulse wave analyses and arterial pulse wave velocity.
After subjects had rested supine for 10 minutes, applanation
tonometry was measured once at the right carotid and
femoral arteries for 10 seconds each, following manufac-
turer’s guidelines (Sphygmocor device; Atcor). Three-lead ECG
recordings were obtained simultaneously with the tonometry
to calculate aortic pulse wave velocity (PWV) (a direct
measure of arterial stiffness). The operator quality index
was 80% in all accepted values used for the study.
Simultaneous microvascular and conduit brachial
endothelial function quantification, assessment of
vascular smooth muscle function and endothelium-
independent nitric oxide responsiveness. Simultaneous
measurement of conduit artery endothelial-dependent and
independent vasodilatation by brachial flow mediated dilata-
tion (FMD) and nitroglycerin mediated dilatation (NMD),
respectively, and of microvascular endothelial-dependent
vasodilatation using the Endo-Pat2000 device (Itamar) was
performed on the dominant arm as previously described by
us.20–24 The end points of these measurements were the
percentage of change in mean brachial and radial diameter in
response to reactive hyperemia (FMD) or to nitroglycerin
(NMD). The reproducibility of these techniques has been
previously reported by our group.22,24
Quantification of circulating markers of CV risk and
inflammation
Quantification of serum inflammatory cytokines,
adhesion molecules and chemokines. Enzyme-linked
immunosorbent assay (ELISAs) were performed following
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manufacturer’s instructions and using a Biotek plate reader
(BioTek Instruments Inc) to quantify serum levels of the
following molecules: monocyte chemoattractant protein-1
(MCP-1) (BD Biosystems), soluble intercellular adhesion
molecule-1 (sICAM-1), soluble vascular cellular adhesion
molecule (sVCAM-1), and interleukin-6 (IL-6) (all from R&D
systems). For circulating IL-17 quantification by ELISA, we used
a protocol previously reported by our group.20
Other laboratory measurements. Total cholesterol, HDL
and LDL cholesterol, triglycerides, insulin, glucose, and high
sensitivity C-reactive protein (hsCRP) were quantified in the
Michigan Diabetes Research and Training Center. Complete
blood count (CBC), liver function tests (LFTs), Westergren
sedimentation rate (ESR), pregnancy test, rheumatoid factor
(RF), and anti-CCP Abs (ACPA) were measured at the central
laboratories at the University of Michigan.
Quantification of insulin resistance. The Homeostasis
Model of Assessment-Insulin Resistance 2 (HOMA-2) was
used to quantify insulin resistance25 as follows: HOMA-IR=
(Glucose [mg/dL]9Insulin [lU/mL])/405. Values >2.5 were
considered consistent with insulin resistance.
Assessment of RA disease activity. Disease Activity Score
28 based on C-reactive protein (DAS-28 CRP)26 was used to
quantify RA disease activity as previously described. The
SF-36 quality of life (QOL) questionnaire27 was also applied to
patients at each visit.
Statistical considerations and analysis. The randomiza-
tion for treatment sequence was conducted using computer-
generated lists stratified for baseline DAS-28 scores and
patients’ age and managed through the University of Michigan
pharmacy. The primary outcome of the study was modifica-
tions in pulse wave velocity (PWV) of the aorta. Secondary
outcomes were changes in other vascular function assess-
ments (FMD, NMD, RHI), as well as RA disease activity. Sample
size formula for a 2-period, 2-treatment crossover design was
used to estimate the detectable treatment effect with the a
level fixed at 0.05 and power at 80%. Standard deviations were
determined from the literature at the time the study was
planned and from pilot studies on similar populations. For FMD
0.5% change was used and for NMD 1.4% change was used. In
addition, the sample size calculation assumed different
possible correlations between observations over time. We
powered the study for differences of 0.26 to 0.36 times the
Figure 1. Study population recruitment summary.
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assumed standard deviations. A 1 in 6 (17%) subject dropout
rate was assumed, so the planned sample size was a total of
120 subjects completing the study. We conducted a repeated
measures analysis of variance including treatment, sequence,
and period effects and incorporated baseline measures on the
primary measures and on QOL. If the tests for sequence and
period effect were not significant they were dropped from the
model. The analysis was conducted on the complete dataset
and restricted to those subjects who completed all assess-
ments (n=108). Continuous variables were summarized using
means and standard deviations (SD) and categorical variables
by counts and percentages. To assess carryover effects, the 2
baseline measures of all outcome variables were compared
using paired t test for normal data or Wilcoxon sign rank test
for non-normal data.
Two sample t tests or Wilcoxon rank sum tests were used to
compare the first period outcomes between the 2 groups.
Because no carryover effect was detected, a paired t test or
Wilcoxon signed rank test was used to compare the change
from baseline to end of treatment for additional known CV and
inflammation markers. A chi square or Fisher’s exact test was
used to compare the rate of various adverse events between
the placebo and treatment groups. An exact binomial test was
used for comparing the dropout rates between those starting
treatment with pioglitazone versus those starting with placebo.
Due to the pilot and hypothesis-generating nature of this study,
no adjustment was used for multiple statistical testing and
multiplicity of outcomes in the sample size calculation. A
P<0.05 was considered significant for all hypothesis tests. The
above procedures were done in SAS 9.3 (SAS Institute Inc).
Results
Patients’ Characteristics and Recruitment
A total of 143 nondiabetic RA subjects were randomized to
participate in the study. Baseline demographics and clinical
characteristics and measurements of vascular function and
inflammation are presented in Tables 1 and 2 and include
information on all subjects enrolled, as well as on completers.
Of patients enrolled, 95% were seropositive for rheumatoid
factor (RF) and 57.3% for anti-CCP antibodies. At baseline,
treatment groups did not significantly differ with respect to RA
disease activity (P=0.4), RA duration (P=0.2), or medications
used to treat RA, including biologics, DMARDs, or corticos-
teroids (P=0.1). There were also no differences between
groups in the Framingham risk equation (P=0.2) or use of
vasoactive medications. Overall, subjects demonstrated high
prevalence of insulin resistance at baseline (113/140
patients [81%]; HOMA-IR2=5.11, 3.44, meanSD). At
baseline, 68.5% of patients were on DMARDs, 46.8% were
on biologics, and 49.6% were on steroids. In addition, 37.7%
of patients were taking a vasoactive drug, 12.5% were on lipid-
lowering agents, and 16.7% took daily aspirin.
Table 1. Baseline Demographic, Clinical Characteristics, and







Gender (females), n (%) 84 (77.8) 109 (76.2)
Race, n (%)
White 98 (90.7) 124 (86.7)
African American 6 (5.6) 13 (9.1)
Asian 2 (1.9) 4 (2.8)
American Indian/Alaska Native 1 (0.9) 1 (0.7)
Other 1 (0.9) 1 (0.7)
Ethnicity (Hispanic), n (%) 5 (4.6) 10 (7.0)
RF (positive), n (%) 105 (97.2) 137 (95.8)
Anti-CCP (positive), n (%) 62 (57.4) 82 (57.3)
Mean (SD) Mean (SD)
Age, y 54.9 (12.5) 55.2 (12.1)
Anti-CCP*, U/mL 31.1 (95) 31.6 (95)
RF*, IU/mL 30.5 (97) 29.0 (81)
DAS28-CRP* 2.8 (1.98) 3.0 (1.91)
Years since RA diagnosis 11.2 (11.2) 11.0 (10.5)
ESR*, mm/h 9.0 (12) 10.0 (12)
Medications, n (%)
Biologics 53 (49.1) 67 (46.85)
Biologics only 2 (3.8) 3 (4.48)
Biologics and DMARD 4 (7.5) 4 (5.97)
Biologics and other† 12 (22.6) 19 (28.36)
Biologics and DMARD and other† 35 (66.0) 41 (61.19)
DMARD 77 (71.3) 98 (68.53)
DMARD only 5 (6.5) 6 (6.12)
DMARD and biologics 4 (5.2) 4 (4.08)
DMARD and others 33 (42.9) 47 (47.96)
DMARD and biologics and other† 35 (45.5) 41 (41.84)
Vasoactive 41 (37.96) 54 (37.76)
Lipid lowering 14 (12.96) 18 (12.58)
Aspirin 18 (16.66) 24 (16.78)
Steroid 53 (49.07) 71 (49.65)
NSAID 58 (53.7) 78 (54.54)
CCP indicates cyclic citrullinated peptide; DAS28-CRP, Disease Activity Score of 28 Joints-
C reactive protein; DMARD, disease modifying anti-rheumatic drug; ESR, erythrocyte
sedimentation rate; IQR, interquartile range; NSAID, nonsteroidal antiinflammatory drugs;
RA, rheumatoid arthritis; RF, rheumatoid factor; SD, standard deviation.
*Median (IQR).
†Other includes vasoactive and lipid-lowering drugs, aspirin, steroids, and NSAIDs.
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There was >90% compliance in enrolled patients, as
measured by pill counts returned at study visits. The dropout
rates were similar between both initially randomized groups:
treatment (19 of 72; 26%) versus placebo (16 of 71; 23%).
Overall, 108 patients completed the study. Figure 1 shows
the flow diagram of the study.
Effect of Pioglitazone on Aortic Compliance
Aortic stiffness, quantified as PWV, significantly decreased
from baseline after 3 months on the pioglitazone treatment
arm, when compared to the placebo arm (0.482.10 m/s
for treatment arm versus 0.271.46 m/s for placebo arm;
P<0.0001). Overall, aortic PWV significantly decreased from
baseline in the pioglitazone arm (P<0.0001), while mean
brachial diastolic BP increased from baseline during pioglit-
azone treatment when compared to the placebo arm
(3.899.78 during pioglitazone versus 9.0886 during
placebo; P=0.02). No significant changes form baseline
occurred in systolic BP. Both mean aortic systolic pressure
and mean aortic pulse pressure significantly improved from
baseline with treatment (5.7513.84 during pioglitazone
versus 0.8213.93 during placebo; P=0.0001 and
4.1612.95 during pioglitazone versus 1.3013.33 during
placebo; P=0.0003), respectively.
Conduit vessel endothelial-dependent vasorelaxation (bra-
chial artery FMD) showed a trend to improve during pioglitazone
treatment but this did not reach statistical significance, nor did
microvascular endothelial function (RHI) significantly improve
during treatment with active drug. Brachial artery vascular
smooth muscle function, as assessed by NMD significantly
increased from baseline during pioglitazone treatment when
compared to the placebo arm (0.321.45% pioglitazone arm
versus 0.201.25% placebo arm; P<0.0001) (Figure 2).
Several markers associated with metabolic disturbances
and CV risk were also significantly modified during the
pioglitazone arm when compared to the placebo arm. Indeed,
HDL levels significantly increased from baseline during pioglit-
azone treatment (5.0713.86 mg/dL pioglitazone versus
0.6413.98 mg/dL placebo; P=0.01), while triglycerides
and hsCRP decreased (16.1344.51 mg/dL pioglitazone
versus 2.0646.79 mg/dL; P=0.01; 1.315.96 mg/dL
pioglitazone versus 0.5411.70 mg/dL placebo; P=0.001,
respectively). Total cholesterol, LDL, and ESR were not
significantly modified during pioglitazone treatment when
compared to the placebo arm. As expected, the mean changes
in HOMA-IR values from baseline were significantly different
between pioglitazone and placebo (0.070.18 during piog-
litazone arm versus 0.030.18 during placebo arm; P≤0.0001).
Similarly, mean insulin levels significantly decreased from
baseline while in the pioglitazone arm (4.369.76 lU/mL on
pioglitazone versus 2.2110.87 lU/mL on placebo;
P≤0.0001). No significant changes in adhesion molecules and
chemokines were observed in the pioglitazone arm when
compared to the placebo arm.
Overall, these observations indicate that short-term treat-
ment with pioglitazone significantly improves vascular function,
particularly large vessel compliance and conduit vessel smooth
muscle function, while also promoting beneficial changes in
inflammatory markers, lipid profile and insulin resistance.
Pioglitazone and RA Disease Activity
When added to standard of care treatment of RA, disease
activity measured by the DAS-28-CRP28 significantly decreased








Brachial SBP, mm Hg 131.5 (17.6) 131.9 (17.7)
Brachial DBP, mm Hg 78.7 (10.7) 78.6 (11.0)
Aortic PP, mm Hg 46.0 (14.9) 45.1 (14.3)
Aortic DP, mm Hg 124.4 (18.4) 123.5 (18.4)
Augmentation index 28.6 (12.0) 28.3 (11.5)
BMI 29.5 (6.7) 29.8 (6.8)
hsCRP, mg/dL 4.2 (6.2) 5.3 (10.5)
Framingham composite
score, %
3.9 (5.3) 3.7 (4.9)
MCP-1*, pg/mL 473.2 (250.77) 471.9 (294.96)
IL-17*, pg/mL 60.5 (642.6) 17.1 (642.3)
IL-6*, pg/mL 1.0 (6.4) 1.4 (6.2)
Total cholesterol, mg/dL 186.8 (41.7) 186.0 (41.7)
Triglycerides, mg/dL 110.4 (59.8) 109.6 (59.5)
HDL, mg/dL 65.3 (18.0) 65.2 (17.7)
LDL, mg/dL 111.3 (35.5) 111.1 (35.2)
Fasting serum insulin, lU/mL 20.3 (10.9) 21.2 (12.3)
Fasting glucose, mg/dL 95.6 (11.6) 95.0 (11.0)
HOMA-IR, mg/dL9lU/mL 5.0 (3.4) 5.1 (3.4)
FMD, % 8.8 (4.2, 48%†) 8.3 (4.0, 48%†)
NMD, % 1.9 (1.6, 84%†) 2.0 (1.6, 80%†)
PWV, m/s 9.0 (2.6, 29%†) 9.2 (2.8, 30%†)
RHI, % 2.1 (0.7, 33%†) 2.1 (0.7, 33%†)
BMI indicates body mass index; CV, cardiovascular; DBP, diastolic blood pressure; FMD,
flow-mediated dilatation; HDL, high-density lipoprotein; HOMA-IR, homeostatic model
assessment-insulin resistance; hsCRP, high-sensitivity C-reactive protein; DP, delta
pressure; IL, interleukin; LDL, low-density lipoprotein; MCP-1, monocyte chemotactic
protein-1; NMD, nitroglycerin-mediated dilatation; PP, pulse pressure; PWV, pulse wave
velocity; RHI, reactive hyperemia index; SBP, systolic blood pressure.
*Median(IQ).
†Coefficient of variation.
DOI: 10.1161/JAHA.113.000441 Journal of the American Heart Association 5















from baseline measurements on the pioglitazone arm when
compared to placebo arm (mean=0.311.2 pioglitazone versus
0.151.2, P=0.02) after 3 months of treatment. QOL, as
assessed by SF-36, did not differ between treatment arms.
Levels of IL-17 and IL-6 and ESR,were not differentiallymodified
between treatment arms, while CRP significantly decreased
during pioglitazone treatment (Figure 2). Overall, these obser-
vations indicate that short-term treatment with pioglitazone
significantly improves RA disease activity and decreases
inflammatory burden when compared to placebo.
Pioglitazone Adverse Events
Patients with RA often present with various comorbidities,
which can make treatments challenging, due to drug inter-
actions and potential adverse effects. In this cohort of
patients with overall low Framingham risk factors and
preserved heart function, markers of target organ function,
including LFTs and CBC were not different between treatment
versus placebo groups at the end of the study. Overall,
pioglitazone was well tolerated. There were more adverse
events while on the active treatment group, and these
consisted primarily of expected side effects related to this
drug class such as weight gain, lower extremity edema, and
dyspnea (Table 3). Of the 16 serious adverse events (SAEs) in
the trial, only one was probably related to the study drug. This
was a case of lower-extremity edema and chest pain that
resolved with discontinuation of the study drug. There were 5
other SAEs considered to be not related to the study drug
including one case of dyspnea and chest pain, one case of
tachycardia and elevated blood pressure, one case of low
potassium and sodium, one hip fracture, and one intracranial
bleed. The study drug was discontinued only for the case of
dyspnea with chest pain, and all resolved. The remainder of
SAEs were considered “definitely not” related to the study
drug.
Figure 2. Change in various CV measures and inflammatory markers during study. Mean change is plotted over time between groups. The dash
line represents the mean change for individuals who started the treatment with pioglitazone; the solid line represents the mean change of
individuals who started the treatment with placebo. CRP indicates C-reactive protein; CV, cardiovascular; DAS28, 28-Joint Disease Activity Scale;
HDL, high-density lipoprotein; HOMA IR, homeostasis model of assessment-insulin resistance; NMD, nitroglycerin mediated dilatation; Pl/Tx,
placebo/treatment group; PWV, pulse wave velocity.
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As CVD now represents one of the most important causes of
morbidity and mortality among patients with RA, it has
become a priority in this and other chronic inflammatory
diseases to identify novel adjuvant therapies that can improve
the aortic compliance and arterial endothelial dysfunction
common among those with RA, while also improving RA
disease activity.
The results of this proof of concept study suggest that
adding pioglitazone to RA standard of care treatment
produces a small but statistically significant improvement in
aortic compliance, decreases RA disease activity, and posi-
tively modulates several markers of CV risk and inflammation.
While there were no improvements in conduit or microvas-
cular endothelial-dependent vasodilatation (ie, unchanged
FMD and RHI), there was a small, but significant increase in
conduit vascular smooth muscle vasodilatory function (NMD).
Previous studies have indicated that RA is associated with
endothelial dysfunction and increased arterial stiffness, in
association with enhanced circulating levels of CRP and
proinflammatory cytokines. These observations have impli-
cated chronic inflammation as an important mediator CVD in
RA.29–31 While the mechanisms for the PWV reduction in our
trial remain speculative, previous meta-analyses indicate that
a 1 m/s increase in PWV corresponds to an age and risk
factor adjusted 14% increase in total CVD events.32 Whether
lowering PWV with treatment directly translates into event
reduction has never been specifically tested; however, the
PWV difference from baseline in our 2 groups was roughly one
half to two thirds (0.75). We acknowledge that the clinical
significance of the reduction in PWV observed in our trial
remains uncertain, and while it represents a favorable
modification in a surrogate marker of CVD health, other
markers (eg, FMD) were not similarly improved. Therefore, the
importance of this isolated reduction in PWV, albeit likely a
reflection of beneficial vascular alterations, on hard clinical
outcomes remains unclear. Extrapolation from the meta-
analysis results suggests it is plausible that the reduced PWV
alone by pioglitazone could produce a 10% reduction in CVD
(in addition to the other vascular and metabolic changes).
Supporting the hemodynamic significance and health rele-
vance of the reduction in PWV, central aortic systolic BP and
pulse pressure (parameters that are also independently
associated with CV risk33) were reduced by treatment. We
recognize that a formal clinical outcome trial testing the
efficacy of pioglitazone would be required to confirm the
clinical importance of these findings.
While the implications of abnormal vascular smooth
muscle function (ie, direct vasodilatory response to NTG,
meaning NMD) in conduit arteries have been less commonly
evaluated or discussed than those for abnormal endothelium-
dependent vasorelaxation, recent evidence in specific patient
populations indicates that NMD adds important information to
conventional CV risk stratification. Indeed, aberrant NMD has
recently been proposed to be an independent predictor of
future CV events, particularly in patients with long-term
exposure to traditional and nontraditional CV risk factors.34–36
Maruhashi et al have provided recent further evidence that
NMD may be an important physiological parameter that is
often overlooked as compared to FMD. They showed in 436
patients that NMD is significantly impaired among patients
with underlying CV disease and is an equal predictor to the
presence of atherosclerosis compared with FMD.37 The
mechanisms responsible for the lack of change in FMD
concomitant with the small increase in NMD in our study
remain unclear. We can speculate, as outlined by Maruhashi
et al, that potential causes could be a small reduction in
vascular oxidative stress that yields an improvement in NMD
but not FMD (as endogenous nitric oxide from endothelial
cells is still overwhelmed by the remaining reactive oxygen
species while the high dose of exogenous NO derived from
NTG can now overcome the oxidative stress). Other possibil-
ities include augmented function of the cCMP cascade within
the smooth muscle cells, or favorable structural remodeling of
the conduit vessels. The biological importance of the NMD
increase also remains speculative. Nonetheless, when taken
together with the reduced PWV and aortic BP values, the
improved NMD suggests that vascular compliance and
perhaps smooth muscle function were enhanced. We
acknowledge that our study was aiming to evaluate a change
in FMD, not NMD. Hence, these results may be chance
Table 3. Adverse Event (AE) by Body System and Treatment
N=143
Body System Placebo (n=127)
Treatment
(n=129) P Value
Body as a whole 3 (2.36%) 5 (3.87%) 0.72
Cardiovascular 4 (3.15%) 8 (6.25%) 0.25
Edema 0 (0.00%) 6 (4.65%) NA
Hemic and lymphatic 0 (0.00%) 1 (3.87%) NA
Infection 5 (3.94%) 5 (3.87%) 1.00
Metabolic and nutritional 3 (2.36%) 4 (3.10%) 1.00
Musculoskeletal 5 (3.94%) 8 (6.25%) 0.57
Nervous system 2 (1.57%) 4 (3.1%) 0.68
Respiratory 1 (0.79%) 6 (4.65%) 0.12
Skin and appendages 4 (3.15%) 3 (2.33%) 0.72
Total number of AEs 27 (21.26%) 50 (38.75%) 0.003
Total number of subjects
with at least one AE
23 (18.11%) 39 (30.23%) 0.028
Values in bold are statistically significant.
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findings. FMD is a more widely accepted vascular marker of
CVD risk compared with NMD. Nevertheless, we consider that
the studies showing a relation between reduced NMD and
CVD supports the conjecture that our findings of improved
NMD with pioglitazone may reflect true positive changes on
vascular health. As arterial stiffness and vascular smooth
muscle function (NMD) predict future CV damage, our
observations support the notion that TZDs can have dual
beneficial effects on RA disease activity and its associated
vascular risk.32 Given the nature of our findings, we consider
these hypothesis-generating results and a future trial is
merited to evaluate the impact of TZD therapy directly on
smooth muscle functionality (eg, NMD) in order to corroborate
these observations.
Our results are in agreement with observations that PPAR-c
signaling pathways play critical roles in the regulation of a
variety of biological processes within the CV system.38–40
Furthermore, TZDs have pleiotropic vasculoprotective roles in
diabetics as well as in other patient populations, including
modulation of CV risk factors, independent of glucose control.
PPAR-c agonists also exert significant anti-inflammatory effects
in experimental arthritis, with reduction in clinical, radiographic,
and histopathologic indicators.18,41 Indeed, PPAR-c ligands
inhibit the growth of RA synoviocytes in vitro and suppress IL-
1b-induced prostaglandin E2 synthesis in RA synovial fibro-
blasts.42 A recent preliminary study in a small sample of RA
patients found a significant improvement in disease activity and
inflammatory markers when 30 mg of pioglitazone were
combined with methotrexate after 12 weeks of treatment.43
All these observations support a potential role for TZDs as
adjuvant therapy in RA and its associated CV risk.
One of the reasons pioglitazone was selected as the TZD to
test in this trial, was the previous evidence that it promotes a
more antiatherogenic lipid profile than rosiglitazone.44 Indeed,
during the pioglitazone treatment arm patients showed a
significant increase in levels of HDL and significant decreases in
triglycerides. These changes may further contribute to vascu-
loprotective effects of pioglitazone in this patient population.
It is important to notice that recent safety issues regarding
the use of TZDs have been raised, due to outcomes of large
placebo-controlled and open-label clinical trials in type 2
diabetics. Both pioglitazone and rosiglitazone have been
associated with fluid retention and heart failure in diabetics,
despite reduced CV morbidity and mortality.45,46 Since RA
patients are at increased risk for heart failure,47 the careful
selection of patients is warranted if these drugs are selected
for use in this disease. Additionally, a concern for malignancy
associated with these medications exists, as a dose-effect
relationship was observed between their use for ≥2 years with
bladder cancer in patients with diabetes.48 Finally, future
studies would need to address how TZDs affect bone health in
RA patients, a group already at heightened risk for osteopo-
rosis due to disease activity and corticosteroid use.49 PPAR
agonist subtypes with selectivity for PPAR-c have been
associated with loss of bone density and strength in animal
models and in clinical trials, due to unfavorable balance
between bone formation and reduction,50 while other PPAR
subtypes have been associated with a protective effect on
bone mineral density in animal models,51,52 However, there is
recent evidence that, in animal models of arthritis, pioglitaz-
one actually prevents inflammatory bone loss.53 As such,
further investigation is required into how these drugs
modulate bone biology in patients with chronic inflammatory
diseases. Given these potential safety concerns, it will be
important to establish whether PPAR-c modulators
(SPPARcMs) or dual PPAR c/a agonists may offer antiather-
ogenic and anti-inflammatory effects without the associated
risks of the current generation of TZDs. In recognition of the
potential side effects and health risks of TZDs and the mixed
benefits in vascular health observed in this trial, future studies
are required to discern the risk versus benefit ratio of
pioglitazone treatment in regards to overall morbidity and
mortality among high-risk RA patients.
Limitations of this study include the relatively small sample
size, the short duration of the trial, and finally an unexpected
finding related to blood pressure changes observed between
groups: while no significant increases in blood pressure were
observed with pioglitazone treatment, there was a small
decrease in blood pressure in the placebo-treated group,
which may be a potential limitation of treatment. However, we
do not believe it outweighs the other potential benefits of
pioglitazone, as aortic SBP, PP, and PWV all improved, and
DBP did not increase, but simply remained stable. The
crossover study design was a strength of this study, as
patients served as their own controls and we found no
evidence for a carryover effect. In general, pioglitazone was
well tolerated in a chronically ill population with a complex
inflammatory disease.
The mechanisms involved in the improvement of vascular
function and large and medium vessels and in RA disease
activity by pioglitazone are likely multifactorial, and associ-
ated with modulation of inflammatory pathways, metabolic
abnormalities, and function of endothelial and vascular
smooth muscle cells. Recent evidence suggests that TZDs
decrease vasoconstriction by inhibiting PI3K/Akt pathway.54
Further, in prediabetes, pioglitazone slows progression of
carotid intima media thickness, independent of improvement
in hyperglycemia, insulin resistance, dyslipidemia, and sys-
temic, suggesting a possible direct vascular benefit.55 It is
important to note that resting brachial BP determined by basal
arteriole tone was not decreased by active treatment. Thus,
the reduction in PWV (ie, improved aortic compliance) cannot
be explained as a consequence of BP-lowering per se or by a
direct hemodynamic action.
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Overall, pioglitazone therapy in this cohort of RA patients
improved disease activity, as evidenced by improvement in
DAS score and decreases in markers of inflammation. How-
ever, pioglitazone use was associated with some significant
cardiovascular side effects, and the positive effects on
macrovascular and conduit artery function were modest. While
at this stage the study does not support the addition of PPAR-c
agonists to standard of care therapy in patients with RA, it will
hopefully add to the growing body of work supporting a
paradigm shift toward prevention of endothelial injury that
leads to atherosclerosis and CV events in RA, and in other
populations of patients with inflammatory diseases.
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